KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 104 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q2 2021. The put-call ratio across all filers is 1.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $430,689 | +11.2% | 24,795 | -9.9% | 0.00% | 0.0% |
| Q2 2023 | $387,468 | +21.1% | 27,519 | -7.5% | 0.00% | 0.0% |
| Q1 2023 | $320,056 | -29.2% | 29,745 | -1.4% | 0.00% | 0.0% |
| Q4 2022 | $451,947 | +31.0% | 30,170 | +12.4% | 0.00% | 0.0% |
| Q3 2022 | $345,000 | +25.0% | 26,851 | -5.8% | 0.00% | 0.0% |
| Q2 2022 | $276,000 | +31.4% | 28,503 | +35.1% | 0.00% | – |
| Q1 2022 | $210,000 | -77.2% | 21,100 | -57.5% | 0.00% | -100.0% |
| Q1 2021 | $920,000 | -3.8% | 49,700 | -8.1% | 0.00% | 0.0% |
| Q4 2020 | $956,000 | +19.9% | 54,100 | +4.0% | 0.00% | 0.0% |
| Q3 2020 | $797,000 | +36.7% | 52,000 | +127.1% | 0.00% | 0.0% |
| Q2 2020 | $583,000 | +75.1% | 22,900 | +6.5% | 0.00% | +100.0% |
| Q1 2020 | $333,000 | +42.3% | 21,500 | +24.3% | 0.00% | 0.0% |
| Q2 2019 | $234,000 | – | 17,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |